MicroDose Therapeutx has dosed its first patient in a Phase I clinical trial of MDT-637, an inhalable antiviral fusion inhibitor designed to treat respiratory syncytial virus.
MDT-637 is formulated for inhaled delivery via MicroDose’s proprietary dry powder nebuliser, a device which allows for the rapid delivery of dry powder medications via tidal inhalation to the site of infection in the respiratory tract.
The US-based, single ascending dose, randomised, placebo controlled Phase I trial is intended to evaluate the safety, tolerability and pharmacokinetics of MDT-637 in 48 healthy adult subjects.
The Phase I trial follows the reactivation of the US IND for MDT-637 as re-formulated for delivery using MicroDose’s proprietary dry powder nebuliser.
MicroDose is developing MDT-637 through Phase IIa clinical trials in collaboration with Gilead Sciences.